PTC raises $15 million

Genetic disorder, cancer and infectious disease play PTC Therapeutics (South Plainfield, N.J.) raised $15 million in the second closing of its series E round, bringing the total raised in the round to $50 million. The round was led by CSFB Private Equity and HBM BioVentures and included new investors Genavent; Novartis BioVentures; and POSCO BioVentures. Existing investors included Bay City Capital; Delphi Ventures; Hansa Special Opportunities Fund; HealthCap; Novo; and Vulcan Capital. ...